Vitamin K3H2

Vitamin K3H2

SCHEMBL2887680

Cc1cc(O)c2ccccc2c1O.[NaH]

nearest known ligand 0.95

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 3/20 0.95
LMNA P02545 1/20 0.95
PKM P14618 2/20 0.61
MAPT P10636 4/20 0.52
KDM4E B2RXH2 3/20 0.52
MEN1 O00255 2/20 0.52
KMT2A Q03164 2/20 0.52
NSD2 O96028 1/20 0.52
POLB P06746 1/20 0.52
MCL1 Q07820 1/20 0.52
HSD17B10 Q99714 2/20 0.50
TP53 P04637 1/20 0.50
GAA P10253 1/20 0.50
THRB P10828 1/20 0.48
TRPM4 Q8TD43 1/20 0.46
IDO1 P14902 1/20 0.46
MAPK1 P28482 2/20 0.45
NPC1 O15118 1/20 0.45
RAB9A P51151 1/20 0.45
CTDSP1 Q9GZU7 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Vitamin K3H2 SCHEMBL29525544 0.98 HTT (1.00) HTTLMNAPKMMAPTKDM4E
Vitamin K3H2 SCHEMBL297164 0.98 HTT (1.00) HTTLMNAPKMMAPTKDM4E
Vitamin K3H2 SCHEMBL27560223 0.90 HTT (0.78) HTTLMNAPKMMAPTKDM4E
Vitamin K3H2 SCHEMBL987810 0.89 HTT (0.75) HTTLMNAPKMMAPTKDM4E
Vitamin K3H2 SCHEMBL515182 0.88 HTT (0.81) HTTLMNAPKMMAPTKDM4E
Vitamin K3H2 SCHEMBL5075246 0.88 HTT (0.81) HTTLMNAPKMMAPTKDM4E
Vitamin K3H2 SCHEMBL516200 0.88 HTT (0.81) HTTLMNAPKMMAPTKDM4E
Vitamin K3H2 SCHEMBL515420 0.88 HTT (0.81) HTTLMNAPKMMAPTKDM4E
Vitamin K3H2 SCHEMBL28664356 0.88 HTT (0.81) HTTLMNAPKMMAPTKDM4E
Vitamin K3H2 SCHEMBL21437091 0.83 HTT (0.72) HTTLMNAPKMMAPTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020044968-A1 High amount of plasticizer to facilitate plasticization of the matrix material at low shear and then reduced prior to adding the encapsulant to reduce post extrusion GENERAL MILLS, INC. 2002-04-18 US claimed
WO-2016118787-A1 ENGINEERED RECEPTOR/LIGAND SYSTEM FOR DELIVERY OF THERAPEUTIC AGENTS UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) 2016-07-28 WO disclosed
US-9272038-B2 Wound care formulation INNOVATION ULSTER LIMITED (GB) 2016-03-01 US disclosed
US-20100286205-A1 WOUND CARE FORMULATION JENARRON THERAPEUTICS LIMITED (GB) 2010-11-11 US disclosed
US-6159931-A Lipid-modified insulin incorporated liposomes for selectively delivering cytotoxic agents to hepatoma cells THE OHIO STATE UNIVERSITY (US) 2000-12-12 US disclosed
WO-1999016425-A1 LIPID-MODIFIED INSULIN INCORPORATED LIPOSOMES FOR SELECTIVELY DELIVERING CYTOTOXIC AGENTS TO HEPATOMA CELLS THE OHIO STATE UNIVERSITY (US) 1999-04-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100286205-A1 WOUND CARE FORMULATION SORD, DAD1, RAP1A HTT 4268/4885LMNA 3301/4885PKM 1277/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.